Christopher David Ozeroff - 14 Dec 2021 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Reporting relationship: S.V.P., General Counsel
Issuer ticker: ORKA
Reported as of: 14 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Dec 2021, 15:33:43 UTC
Prior SEC filing: 23 Nov 2021
Source filing: View source filing
Reporting owner signature: /s/ C. Jeffrey Dekker, Attorney-in-Fact

Key filing fact

Christopher David Ozeroff filed Form 4 for ARCA biopharma, Inc. (ORKA) on 16 Dec 2021.

Key facts

This page summarizes Christopher David Ozeroff's Form 4 filing for ARCA biopharma, Inc. (ORKA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Dec 2021, 15:33.

Change

Previous filing in this sequence was filed on 23 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABIO holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 50,970
Date: 14 Dec 2021
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABIO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +27,500
Change %
Price: $0.000000
Shares after: 27,500
Date: 14 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,500
Exercise price: $2.29
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.